Biology Reference
In-Depth Information
85. Amarzguioui M, Lundberg P, Cantin E, Hagstrom JE, Behlke MA, Rossi JJ (2006) Rational
design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc 1(2):508-517
86. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MO et al (2006) RNA
interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther
14(4):476-484
87. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R et al (1995) CpG
motifs in bacterial DNA trigger direct B-cell activation. Nature 374(6522):546-549
88. Thiel KW, Giangrande PH (2009) Therapeutic applications of DNA and RNA aptamers.
Oligonucleotides 19(3):209-222
89. Zhou J, Rossi JJ (2010) Aptamer-targeted cell-specific RNA interference. Silence 1(1):4
90. Syed MA, Pervaiz S (2010) Advances in aptamers. Oligonucleotides 20(5):215-224
91. Zhou J, Li H, Li S, Zaia J, Rossi JJ (2008) Novel dual inhibitory function aptamer-siRNA
delivery system for HIV-1 therapy. Mol Ther 16(8):1481-1489
92. Zhou J, Swiderski P, Li H, Zhang J, Neff CP, Akkina R et al (2009) Selection, characteriza-
tion and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate
siRNAs into HIV infected cells. Nucleic Acids Res 37(9):3094-3109
93. Davidson BL, McCray PB Jr (2011) Current prospects for RNA interference-based therapies.
Nat Rev Genet 12(5):329-340
94. Burnett JC, Rossi JJ, Tiemann K (2011) Current progress of siRNA/shRNA therapeutics in
clinical trials. Biotechnol J 6(9):1130-1146
95. De Paula D, Bentley MV, Mahato RI (2007) Hydrophobization and bioconjugation for
enhanced siRNA delivery and targeting. RNA 13(4):431-456
96. de Fougerolles AR (2008) Delivery vehicles for small interfering RNA in vivo. Hum Gene
Ther 19(2):125-132
97. Howard KA, Kjems J (2007) Polycation-based nanoparticle delivery for improved RNA
interference therapeutics. Expert Opin Biol Ther 7(12):1811-1822
98. Howard KA (2009) Delivery of RNA interference therapeutics using polycation-based nano-
particles. Adv Drug Deliv Rev 61(9):710-720
99. Tseng YC, Mozumdar S, Huang L (2009) Lipid-based systemic delivery of siRNA. Adv Drug
Deliv Rev 61(9):721-731
100. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling,
cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6(3):659-668
101. Eguchi A, Dowdy SF (2009) siRNA delivery using peptide transduction domains. Trends
Pharmacol Sci 30(7):341-345
102. Jarver P, Mager I, Langel U (2010) In vivo biodistribution and efficacy of peptide mediated
delivery. Trends Pharmacol Sci 31(11):528-535
103. Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA (2010) Gold
nanoparticles for biology and medicine. Angew Chem Int Ed Engl 49(19):3280-3294
104. Serda RE, Godin B, Blanco E, Chiappini C, Ferrari M (2011) Multi-stage delivery nano-
particle systems for therapeutic applications. Biochim Biophys Acta 1810(3):317-329, Epub
2010/05/25
105. Peer D, Lieberman J (2011) Special delivery: targeted therapy with small RNAs. Gene Ther
18(12):1127-1133
106. Sanghvi YS, Schulte M (2004) Therapeutic oligonucleotides: the state-of-the-art in
purification technologies. Curr Opin Drug Discov Devel 7(6):765-776
107. Tedebark U, Scozzari A, Werbitzky O, Capaldi D, Holmberg L (2011) Industrial-scale manu-
facturing of a possible oligonucleotide cargo CPP-based drug. Methods Mol Biol 683:505-524,
Epub 2010/11/06
Search WWH ::
Custom Search